Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- α versus toxicity after melphalan alone

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.

D Liénard, Patricia Ewalenko, Jean-Baptiste Delmotte et al. · Journal of Clinical Oncology · 1992 · 723 citations

Pharmacy, Oncology, Pharmacotherapy +17

Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions

J Wieberdink, C. Benckhuysen, R. P. Braat et al. · European Journal of Cancer and Clinical Oncology · 1982 · 458 citations

Medicine, Pharmacology, Toxicology +14

Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity Sarcomas

Alexander M.M. Eggermont, Heimen Schraffordt Koops, Joseph M. Klausner et al. · Annals of Surgery · 1996 · 457 citations · Full text

Medicine, Oncology, Surgery +16

Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.

Hs Koops, Maurizio Vaglini, Stefan Suciu et al. · Journal of Clinical Oncology · 1998 · 246 citations

Medicine, Oncology, Surgery +17

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.

Douglas L. Fraker, H. Richard Alexander, Mary P. Andrich et al. · Journal of Clinical Oncology · 1996 · 212 citations

Medicine, Oncology, Pharmacotherapy +17